In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
about
Application of a microcalorimetric method for determining drug susceptibility in mycobacterium speciesCurrent prospects for the fluoroquinolones as first-line tuberculosis therapyAntituberculosis therapy for 2012 and beyondCurrent strategies to treat tuberculosisIntensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.Epidemiology and treatment of multidrug resistant tuberculosisBactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial.In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867Fish tank granuloma caused by Mycobacterium marinumSusceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?New drugs to treat tuberculosis.In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in JapanEfficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project.Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression ModelsMoxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.Evaluation of Moxifloxacin-induced Biochemical Changes in MiceEarly and extended early bactericidal activity of linezolid in pulmonary tuberculosisContribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Levofloxacin-proliposomes: opportunities for use in lung tuberculosis.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010.De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.Is repositioning of drugs a viable alternative in the treatment of tuberculosis?Therapeutic drug monitoring in the treatment of tuberculosis: an update.Optimizing the clinical pharmacology of tuberculosis medications.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
P2860
Q24611042-9297D1DC-6BC5-4142-8683-525E23B039CFQ26823843-AC14786A-2A37-45B4-8345-2139447858CEQ26829101-6652EAE7-6CCF-4493-988E-89901DF512EBQ28075252-4BF543E0-1726-4615-A213-AC1E5934034BQ30498213-32B4CC1A-5DB9-4977-9EEC-E388CBDD3596Q30834393-CBDC0D8A-ECD9-4B97-841C-652EAC374FE1Q33710690-B6F3541F-ADE5-4185-BA62-BEA167CC3B4DQ33805878-78DAE195-15EA-4DA6-92F4-1A6A2282F15CQ33810454-3354C459-23C9-4FA4-88C7-398A0AEC7A96Q34076988-2F0888C1-045A-4546-A7C8-65D020EFFA42Q34387801-A3EBC97C-A6D9-478A-B9BA-31442C66AE36Q34737298-4D339170-176C-49E7-B4DC-2361CE9DE8EFQ35065890-72BF77A0-6E91-4939-B0CC-971EEF39ECA4Q35139691-12F11FB2-3D9B-4318-BA2A-1CD6445BD50CQ35197257-1943B012-7DAB-47B4-B88A-4C4341660FCAQ35849799-922930F7-EF95-46E4-B818-7410DA622905Q36018409-E1762117-A6BD-4239-91D7-42559A7601A9Q36295387-BC74D234-B17B-4AB4-92AB-D15B96155156Q36347436-78521482-9754-46DA-B7F7-A37FA72E28A2Q36483331-F9A93B18-6D4C-4F28-868B-7DC408C348CAQ36492180-4E5CF16F-4A7F-47AF-8840-E2D9042B5E1EQ36620071-91A3A80B-6B58-4DA0-A1A5-6CE42E600FB9Q36650622-B64BAD77-3D0B-4D41-B344-913C66086ADDQ36703055-09DABF73-1203-4AC7-B2A8-8E3CB3F7F1D5Q36865298-F1E114DA-563C-4F34-B7FC-146A948E6119Q36986669-17DB9222-2C54-4E66-98D0-4524468CE36EQ37074826-8C8177A6-814E-4077-A27C-9B1F617677D2Q37124090-9FB372AB-2FCA-4A48-BFFC-82265731DF72Q37327834-C1E94959-6936-464D-967D-6EC23CF1AD37Q37339290-2408FC2C-CAC5-4271-A857-5B3CA2A963CDQ37346929-BD253B22-0DFF-4A2D-B787-E234D12DD0DAQ37612926-EA0660CD-A144-4CF4-8FDD-16071082A652Q37612996-38A820BE-2890-465B-9960-0FAB5DB745D3Q37712966-F08032E7-4D14-45D4-8946-992DCC156AFEQ38053000-40C5059B-F9ED-49AD-9941-A59CC52FACB1Q38213320-B9D08FB2-F2FC-4F4A-8EAC-9B1098D58CC3Q38542159-FF546016-0B47-4915-A3CD-CC54548A939DQ38845761-87CBB336-D9B7-410C-A262-6A90EFF0C032Q39398946-D8595D75-0A42-4771-A5EC-EA96E927BD4FQ39895097-26AC2390-F8DB-4391-95AF-D0D2364F89BE
P2860
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
In vitro activity of moxifloxa ...... st Mycobacterium tuberculosis.
@en
In vitro activity of moxifloxa ...... st Mycobacterium tuberculosis.
@nl
type
label
In vitro activity of moxifloxa ...... st Mycobacterium tuberculosis.
@en
In vitro activity of moxifloxa ...... st Mycobacterium tuberculosis.
@nl
prefLabel
In vitro activity of moxifloxa ...... st Mycobacterium tuberculosis.
@en
In vitro activity of moxifloxa ...... st Mycobacterium tuberculosis.
@nl
P2093
P1476
In vitro activity of moxifloxa ...... st Mycobacterium tuberculosis.
@en
P2093
P304
P356
10.1016/S0924-8579(02)00239-X
P577
2002-12-01T00:00:00Z